GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » Total Current Liabilities

APLT (Applied Therapeutics) Total Current Liabilities : $27.30 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Applied Therapeutics's total current liabilities for the quarter that ended in Dec. 2024 was $27.30

Applied Therapeutics Total Current Liabilities Historical Data

The historical data trend for Applied Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics Total Current Liabilities Chart

Applied Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
Get a 7-Day Free Trial 21.24 26.46 33.42 71.18 27.30

Applied Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.18 83.91 55.36 98.97 27.30

Applied Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Applied Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=15.744+0.406
+Other Current Liabilities+Current Deferred Liabilities
=10.934+0.212
=27.30

Applied Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=15.744+0.406
+Other Current Liabilities+Current Deferred Liabilities
=10.934+0.212
=27.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Applied Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » Total Current Liabilities
Comparable Companies
SKYE DTIL PDSB CTMX VICP IKNA CYCC VTVT SER QNCX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
2UV:Germany 2UV:Germany
Address
545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017
Website
https://www.appliedtherapeutics.com
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Executives
Riccardo Perfetti officer: Chief Medical Officer C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman director, 10 percent owner, officer: President and CEO C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc. 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Adam Hansard officer: Chief Commercial Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Stacy J. Kanter director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Catherine Thorpe officer: Chief Accounting Officer 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan officer: Chief Accounting Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega officer: Principal Accounting Officer C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein officer: Chief Financial Officer C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler director DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173

Applied Therapeutics Headlines

From GuruFocus

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

By Business Wire • 02-18-2025

APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit

By PRNewswire • 02-16-2025

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results | APLT Stock News

By GuruFocus News • 04-14-2025

Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

By PRNewswire • 02-13-2025

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

By Marketwired • 03-19-2025

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results

By Marketwired • 04-14-2025

Applied Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 - APLT

By PRNewswire • 02-14-2025

DEADLINE ALERT for APLT and KSPI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

By Marketwired • 02-18-2025

INVESTOR DEADLINE TOMORROW: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - APLT

By PRNewswire • 02-17-2025

APLT DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - APLT

By Marketwired • 02-14-2025